Multiplexed IHC analysis to enable Hodgkin lymphoma differential diagnosis on a single slide.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19536-e19536
Author(s):  
Lawrence Weiss ◽  
Alexander Bordwell ◽  
Alex Corwin ◽  
Dave Henderson ◽  
Denise Hollman- Hewgley ◽  
...  

e19536 Background: Routine diagnosis of classical Hodgkin lymphoma is performed with a panel of immunohistochemistry markers to evaluate the biomarker expression profile of the relatively rare Hodgkin cells. One of the key challenges of this technique is that serial immunostains are used and hence it can be difficult or impossible to locate the same Hodgkin cell on adjacent slides. Given the rarity of the Hodgkin cells coupled with the number of markers that are needed for a definitive diagnosis, we developed a new technique in which a single patient slide is multiplexed with nine different antibodies . Methods: One FFPE tissue section from 11 cases was probed for the following nine biomarkers: CD30, CD15, CD45, Pax5, CD20, CD79a, OCT2, Bob1, and CD3. An initial 10x whole slide fluorescent image of CD30 was acquired and presented to the pathologist who based on this staining selected regions of interest for higher magnification (40x) imaging of the CD30 and the other antibodies. The fluorescent images acquired were processed for interpretation using an in-house developed viewing tool. The pathologist was able to view each biomarker as a standard grayscale, monochromatic image, an overlay of two or more biomarkers, or as a virtually created molecular DAB image. Results: A correct diagnosis of classical Hodgkin lymphoma vs. other was able to be made using the MultiOmyx platform in all cases. Subjectively, the pathologist noted that the novel methodology allowed for a significantly more confident assessment of marker expression on the Hodgkin cells in the seven cases of classical Hodgkin lymphoma, eliminating many issues of staining ambiguity and allowing recognition of subtle nuances of staining intensity in the Hodgkin cells. The CD30+ cells in the four other cases, three cases of B-cell lymphoma and one case of lymphocyte predominance Hodgkin lymphoma, showed a B-cell profile that was distinguishable from the classical Hodgkin cell phenotype. Conclusions: This new method of fluorescent multiplexing on a single tissue section allows more accurate interpretation of the biomarker expression profile on the same Hodgkin cell. It is likely that this paradigm can be expanded to a greater range of challenging cases in hematopathology.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2994-2994 ◽  
Author(s):  
Alisha Adams ◽  
Alexander Bordwell ◽  
Derek Bouman ◽  
Deanna Fisher ◽  
Denise Hollman ◽  
...  

Abstract Background/Introduction The diagnosis of classical Hodgkin lymphoma is often difficult to establish due to the rarity of the neoplastic component and the necessity to perform immunostains on serial sections. We have developed a fluorescent multiplexed methodology in formalin-fixed, paraffin-embedded sections which enables assessment of multiple antigens on a single tissue section and allows evaluation of specific cells within specific fields (MultiOmyxTM). In this clinical application, we assessed CD30-positive cells with eight additional antibodies on the same piece of tissue as an aid to the diagnosis of classical Hodgkin lymphoma. Methods One formalin-fixed tissue section from each of the 56 cases was probed with fluorescently conjugated antibodies against the following nine biomarkers: CD30, CD15, CD45, Pax5, CD20, CD79a, OCT2, Bob1, and CD3 (Fig. 1). An initial 10x whole slide fluorescent image of CD30 was acquired and presented to the pathologist who, based on this staining, selected regions of interest for higher magnification (40x) imaging of the CD30 and the other antibodies to facilitate assessment. The fluorescent images acquired were processed for interpretation using an in-house developed viewing tool. The pathologist was able to view each biomarker as a standard grayscale, monochromatic image, an overlay of two or more biomarkers, or as an algorithmically generated molecular diaminobenzidine (DAB) image resembling a bright field approach. Results The staining characteristics were studied in a series of 23 cases. Individual antibody specificity was found to be 100% in all but one marker assessed; CD30 was found to be discordant in 1 of the 23 samples. Inter- and intraday concordance was 100%. Fifty-six unique cases were studied for diagnostic concordance. We compared historical diagnosis using immunohistochemistry to the MultiOmyxTM diagnosis, studying blinded cases of classical Hodgkin lymphoma and other differential diagnosis entities. Additionally, we included nodular lymphocyte predominance Hodgkin lymphoma, T-cell rich B-cell lymphoma, peripheral T-cell lymphoma, including anaplastic large cell lymphoma, and reactive immunoblastic proliferations. Fifty-four of the 56 cases showed complete concordance. One case was diagnosed as equivocal on initial historical diagnosis, but subsequent rebiopsy diagnosis showed concordance with the MultiOmyxTM diagnosis derived from the initial specimen. One other case was discordant with the historical diagnosis (case was studied five independent times by MultiOmyxTM, all with same diagnosis), and retrospective analysis of the case raised doubt as to the validity of the historical diagnosis. Discussion MultiOmyxTM single slide assay has similar staining characteristics and is at least equivalent to standard immunohistochemical stains. It allows for better correlation of results between stains in a given case, particularly in cases with rare Hodgkin cells, since it allows direct comparison of stains within the same field of view and on the same cells. In addition, MultiOmyxTM may be advantageous in small samples, in which full immunohistochemical profiles may not be possible. MultiOmyxTM allowed improved assessment of Hodgkin cells for antigens expressed on other cell types (e.g., B-cell antigens on reactive immunoblasts, or CD15 on reactive histiocytes), as well as antigens expressed on directly adjacent cells (e.g., CD45 and CD3). This novel methodology is practical for routine diagnosis, and will likely be an aid to the improved diagnosis of Hodgkin lymphoma. Disclosures: No relevant conflicts of interest to declare.


2016 ◽  
Vol 2 (5) ◽  
pp. 292
Author(s):  
Pardis Vafaii ◽  
Haipeng Shao

Classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma rarely develop in the same patient synchronously or metachronously. Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma. An intermediate stage of transformation was identified with scattered Reed-Sternberg/Hodgkin cells present in a background of the DLBCL cells. These Reed- Sternberg/Hodgkin cells showed typical immunophenotype of cHL cells and were associated with limited inflammatory cells. While Reed-Sternberg/Hodgkin-like cells are not uncommonly seen in a variety of non-Hodgkin lymphomas, the subsequent development of cHL in this patient indicated that the scattered Reed-Sternberg/Hodgkin cells among DLBCL cells truly represented a precursor of cHL. This would be extremely challenging, if not impossible, for pathologists to diagnose. We also highlight the importance of clinicopathological correlation and the crucial role of additional biopsies.


2016 ◽  
Vol 2 (5) ◽  
pp. 242
Author(s):  
Editorial Office

<div>An uncommon case of blood cancer non-Hodg- kin lymphoma developing into classical  Hodgkin lymphoma was recently described by researchers from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in a case report published in this issue of AMOR.</div><p> </p><p>“Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma (cHL),” said pathologists Dr. Haipeng Shao and Pardis Vafaii from the Department of Hematopathology and Laboratory Medicine. “To the best of our knowledge, this is the first report of an intermediate stage of transformation from DLBCL into cHL,” they added.</p><p> </p><p>Lymphoma, or cancer in the infection-fighting lymphatic part of a human’s immune system, is categorized into two types: Hodgkin lymphoma and non-Hodgkin lymphoma – both with distinct behaviors and different treatment requirements. Classical Hodgkin lymphoma – named after the 19<sup>th</sup> century British physician Thomas Hodgkin who first described the abnormalities in lymphatic system – is a less frequently diagnosed lymphoma subtype with tell-tale signs of abnormal lymphoid cells called ‘Reed­Sternberg cells’ which are observed as giant purple nucleoli when examined under light microscopy.</p><p> </p><p>However, 90% of lymphomas are of the non-Hodgkin lymphoma variety and do not exhibit the Reed­Sternberg cells. Of all the non-Hodgkin lymphomas, DLBCL is the most common type, which develops when white blood cells called lymphocytes (specifically the B-cell lymphocytes) start dividing uncontrollably. The distinction between DLBCL and cHL is clinically important as both respond differently to chemotherapeutic regimens, according to Shao and Vafaii. Moreover, “classical Hodgkin lymphoma and non-Hodgkin lymphoma rarely develop in the same patient,” they explained.</p><p> </p><p>In their published case report, however, DLBCL and cHL was found to develop on the same anatomic sites, particularly on the skin of the patient, evidenced by the presence of cHL following the occurrence of DLBCL. The patient was an elderly male with a history of stage IV DLBCL. Biopsies taken from the patient’s left arm and upper back revealed results consistent with DLBCL of the non-germinal center subtype. The patient then underwent chemotherapy, salvage therapy, and an autologous bone marrow transplant. Following the transplant, the patient’s biopsies started manifesting features of cHL, indicating a hybrid intermediate stage, according to the authors. “In the second biopsy…scattered Reed -Sternberg/Hodgkin-like cells were admixed with the DLBCL cells,” Shao and Vafaii wrote of the large atypical lymphoid cells which resemble Reed-Sternberg in cHL but do not develop into cHL.</p><p> </p><p>Nonetheless, despite these Reed-Sternberg/Hodgkin- like cells showing typical immunophenotype of cHL cells and were associated with limited inflammatory cells, “cHL diagnosis requires the presence of expansile lesion with a characteristic mixed inflammatory background as- sociated with Reed-Sternberg/Hodgkin cells,” the authors explained, and “the Reed-Sternberg/Hodgkin-like cells did not seem to elicit a mixed inflammatory reaction and form a discrete mass lesion within the large lymphoid cells,” hence rendering it difficult for the pathologists to diagnose cHL at this stage.</p><p> </p><p>Three months later, however, an excisional biopsy performed on the patient’s lymph node no longer showed evidence of DLBCL but instead exhibited “many scattered clusters of Reed-Sternberg/Hodgkin cells with prominent cherry-red nucleoli in a background of small mature lymphocytes and granulocytes,” which are findings consistent with a cHL of the nodular sclerosis subtype, Shao and Vafaii reported.</p><p> </p><p>The diagnosis of cHL established in the final lymph node biopsy therefore demonstrated that the Reed- Sternberg/Hodgkin-like cells found in the intermediate stage signaled the progression of DLBCL into cHL. “While Reed-Sternberg/Hodgkin-like cells are not uncommonly seen in a variety of non-Hodgkin lymphomas, the subsequent development of cHL in this patient indicated that the scattered Reed-Sternberg/Hodgkin cells among DLBCL cells truly represented a precursor of cHL,” the authors said, adding that the transformation would be possible for pathologists to diagnose, albeit very challenging.</p><p> </p><p>Furthermore, “the identification of a hybrid intermediate stage suggested that [cHL and DLBCL] were clonally related,” they said. Further analysis of the genetic changes responsible for cHL transformation could possibly be done by examining individual Reed-Sternberg/ Hodgkin-like cells in the precursor stage, as well as the cHL cells in later stages, with subsequent molecular studies such as laser capture microdissection or next generation sequencing, their report proposed.</p><p> </p><p>According to Shao and Vafaii, the case report was unique in which a stepwise transformation from DLBCL into cHL was demonstrated through a series of biopsies, which highlights the importance of repeated biopsies in diagnostically-challenging case. “Precursor or early lesions that could not be initially established diagnostically would eventually manifest themselves in later biopsies,” the authors concluded. </p><div> </div><p> </p>


2016 ◽  
Vol 104 (3) ◽  
pp. 396-399 ◽  
Author(s):  
Shinichi Makita ◽  
Akiko Miyagi Maeshima ◽  
Hirokazu Taniguchi ◽  
Hideaki Kitahara ◽  
Suguru Fukuhara ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 19-19 ◽  
Author(s):  
Marc A. Weniger ◽  
Ingo Melzner ◽  
Christiane K. Menz ◽  
Silke Wegener ◽  
Alexandra J. Bucur ◽  
...  

Abstract The suppressors of cytokine signaling (SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma (PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P (BLOOD, 105, 2535–42, 2005). For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma (HL)-derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue (p<0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3664-3664
Author(s):  
Catherine H Burton ◽  
Sheila J.M. zsnO'Connor ◽  
Roger G Owen ◽  
Andrew S Jack

Abstract Abstract 3664 Poster Board III-600 Classical Hodgkin lymphoma in association with another type of B-cell malignancy is a well recognised entity. In at least some of these composite lymphoma cases, a clonal relationship between the lymphoma sub-types can be demonstrated by the presence of common cytogenetic abnormalities or mutational patterns within the IGH locus. There is little known of possible mechanisms of clonal divergence in these cases. It is possible that treatment or the tumour micro-environment could, in some circumstances, favour the outgrowth of Reed Sternberg cells. These cells having lost many central phenotypic characteristics of mature B-cells may have an advantage over clonal tumour cells that remain under the control of normal regulatory pathways. In such a model, treatment with rituximab could add selective pressure favouring the development of a composite lymphoma. We have recently identified three male patients who relapsed with classical Hodgkin lymphoma after treatment for another form of B-cell malignancy. Patient 1, aged 76 years, had stage 3, asymptomatic follicular lymphoma, and was treated with rituximab alone. Eight months from the original diagnosis he developed new submental lymphadenopathy. Patient 2, aged 49 years, had stage four, symptomatic follicular lymphoma, treated with R-CVP. He developed biopsy proven high grade transformation at the end of his treatment and proceeded to two cycles of R-DHAP. At the end of treatment, twelve months from the original diagnosis, he developed inguinal lymphadenopathy. Patient 3, aged 70 years, had stage four, diffuse large B-cell lymphoma, treated at presentation with R-CHOP. Two years after initial diagnosis, he developed cervical lymphadenopathy. In all three presenting cases, CD20 was strongly expressed on the lymphoma cells and a t(14;18) was identified in the biopsy. In all three relapsed cases the biopsy showed morphologically typical classical Hodgkin lymphoma with CD30/IRF4 co-expression and absence of Oct2, Bob1 and CD20 expression within the Reed Sternberg cells. A t(14;18) was detected by FISH in the Reed Sternberg cells, demonstrating clonal identity with the underlying lymphoma. There was no evidence of the preceding lymphoma and complete absence of a normal B-cell population in the biopsy. Epstein Barr Virus was not detectable by EBER in situ hybridisation. All patients have been treated for Hodgkin lymphoma. Patient 1 has subsequently died, patient 2 is awaiting a stem cell transplant and patient 3 is currently receiving treatment. Treatment with rituximab is associated with the development of CD20 negative phenotypic change. In some cases this may be due to the selection of tumour cells that have epigenetically silenced the expression of CD20. Epigenetic silencing of key transcription factors may also be the mechanism of loss of the B-cell phenotype, including CD20, in Reed Sternberg cells. The relatively frequent occurrence of composite lymphoma suggests that this may occur regularly with neoplastic B-cell populations and the outgrowth of these cells would be strongly favoured by rituximab treatment. The cases presented here highlight the need for a more systematic approach to the collection of data from patients with relapsed lymphoma. An association between rituximab treatment and the development of composite lymphoma has practical consequence but may also provide a unique insight into the pathogenesis of Hodgkin lymphoma. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 266-266 ◽  
Author(s):  
Enrico Tiacci ◽  
Verena Brune ◽  
Susan Eckerle ◽  
Wolfram Klapper ◽  
Ines Pfeil ◽  
...  

Abstract Abstract 266 Background. Previous gene expression profiling studies on cHL have been performed on whole tissue sections (mainly reflecting the prominent reactive background in which the few HRS cells are embedded), or on cHL cell lines. However, cultured HRS cells do not likely reflect primary HRS cells in all aspects, being derived from end-stage patients and from sites (e.g. pleural effusions or bone marrow) which are not typically involved by cHL and where HRS cells lost their dependence on the inflammatory microenvironment of the lymph node. Methods. ∼1000–2000 neoplastic cells were laser-microdissected from hematoxylin/eosin-stained frozen sections of lymph nodes taken at disease onset from patients with cHL (n=16) or with various B-cell lymphomas (n=35), including primary mediastinal B-cell lymphoma (PMBL) and nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL). After two rounds of in vitro linear amplification, mRNA was hybridized to Affymetrix HG-U133 Plus 2.0 chips. Expression profiles were likewise generated from sorted cHL cell lines and several normal mature B-cell populations. Results. Primary and cultured HRS cells, although sharing hallmark cHL signatures such as high NF-kB transcriptional activity and lost B-cell identity, showed considerable transcriptional divergence in chemokine/chemokine receptor activity, extracellular matrix remodeling and cell adhesion (all enriched in primary HRS cells), as well as in proliferation (enriched in cultured HRS cells). Unsupervised and supervised analyses indicated that microdissected HRS cells of cHL represent a transcriptionally unique lymphoma entity, overall closer to nLPHL than to PMBL but with differential behavior of the cHL histological subtypes, being HRS cells of the lymphocyte-rich and mixed-cellularity subtypes close to nLPHL cells while HRS cells of NS and LD exhibited greater similarity to PMBL cells. HRS cells downregulated a large number of genes involved in cell cycle checkpoints and in the maintenance of genomic integrity and chromosomal stability, while upregulating gene and gene signatures involved in various oncogenic signaling pathways and in cell phenotype reprogramming. Comparisons with normal B cells highlighted the lack of consistent transcriptional similarity of HRS cells to bulk germinal center (GC) B cells or plasma cells and, interestingly, a more pronounced resemblance to CD30+ GC B cells and CD30+ extrafollicular B cells, two previously uncharacterized subsets that are transcriptionally distinct from the other mature B-cell types. Conclusions. Gene expression profiling of primary HRS cells provided several new insights into the biology and pathogenesis of cHL, its relatedness to other lymphomas and normal B cells, and its enigmatic phenotype. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5282-5282
Author(s):  
Naoko Asano ◽  
Kazuhito Yamamoto ◽  
Jun-Ichi Tamaru ◽  
Takashi Oyama ◽  
Fumihiro Ishida ◽  
...  

Abstract Age-related Epstein-Barr virus-associated (EBV+) B-cell lymphoproliferative disorder (LPD) is a disease group of EBV+ large B-cell lymphoma characteristically seen in elderly patients without predisposing immunodeficiency. This disease is now going to be listed in the up-coming WHO classification the 4th version. Age-related EBV+ LPD, especially of a polymorphous subtype, which occupied about one-third of cases, is often featured by a rich infiltration of reactive cells in the background, posing the differential diagnostic issue with classical Hodgkin lymphoma (cHL) associated with EBV. However, the clinicopathological differentiation between these two EBV-positive diseases remains to be elucidated. The aim of this study is to clarify the clinicopathological differences between the polymorphic subtype of age-related EBV+ LPD (n=34) and EBV+ cHL (n=108) of patients of 50 years and more of age. Age-related LPD was more closely associated with the following clinical parameters than cHL: a higher age at onset (71 vs. 63 years), lower male predominance (male:female ratio, 1.4 vs. 3.3), and a higher ratio of involvement of the skin (18% vs. 2%), the gastrointestinal tract (15% vs. 4%) and the lung (12% vs. 2%). Furthermore, age-related LPD was histopathologically characterized by a higher ratio of geographical necrosis, a greater increase (&gt;30%) of cytotoxic T cells in the background lymphocytes, a higher positive rate for CD20 and EBNA2 together with an absence of CD15 expression than EBV+ cHL. As predicted by the clinical profile, age-related LPD had a significantly poorer prognosis than EBV+ cHL (P = 0.0001). This analysis has clearly demonstrated that the polymorphous subtype of age-related LPD constitutes an aggressive group with an immune response distinct from those of EBV+ cHL.


Sign in / Sign up

Export Citation Format

Share Document